In vivo prime editing rescues alternating hemiplegia of childhood in mice
Cell · 2025-08 · 188 (16) · 4275-4294.e23
DOI: 10.1016/j.cell.2025.06.038 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell, 2025-08. Verfasst von Alexander A Sousa und 18 weiteren Autor:innen. Beteiligte Einrichtung: Merkin Institute of Transformative Technologies in Healthcare, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, M…. Hauptthemen laut MEDLINE: Sodium-Potassium-Exchanging ATPase, Hemiplegia, Gene Editing. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 168 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NHGRI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Alternating hemiplegia of childhood (AHC) is a neurodevelopmental disorder with no disease-modifying treatment. Mutations in ATP1A3, encoding an Na+/K+ ATPase subunit, cause 70% of AHC cases. Here, we present prime editing (PE) and base editing (BE) strategies to correct ATP1A3 and Atp1a3 mutations in human cells and in two AHC mouse models. We used PE and BE to correct five prevalent ATP1A3 mutations with 43%-90% efficiency. AAV9-mediated in vivo PE corrects Atp1a3 D801N and E815K in the CNS of two AHC mouse models, yielding up to 48% DNA correction and 73% mRNA correction in bulk brain cortex. In vivo PE rescued clinically relevant phenotypes, including restoration of ATPase activity; amelioration of paroxysmal spells, motor defects, and cognition deficits; and dramatic extension of animal lifespan. This work suggests a potential one-time PE treatment for AHC and establishes the ability of PE to rescue a neurological disease in animals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Merkin Institute of Transformative Technologies in Healthcare, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA; Department of Chemistry and Chemical Biology, Harvard Un…
- Rare Disease Translational Center, The Jackson Laboratory, Bar Harbor, ME 04609, USA.
- Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
- Department of Neurosurgery, Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Medical School, Boston, MA 02115, USA.
- RARE Hope, Washington, DC, USA.
- Department of Genetics & Cellular Medicine, Horae Gene Therapy Center, Li Weibo Institute for Rare Diseases Research, UMass Chan Medical School, University of Massachusetts, Worcester, MA 01605, USA; Department of Micro…
Förderung
- NINDS NIH HHS
- NHGRI NIH HHS
- NIGMS NIH HHS
- NIH HHS
- Davis Family Foundation
- Howard Hughes Medical Institute
- National Institutes of Health
- National Science Foundation
Zitieren
APA
Sousa, A. A., Terrey, M., Sakai, H. A., Simmons, C. Q., Arystarkhova, E., Morsci, N. S., Anderson, L. C., Xie, J., Suri-Payer, F., Laux, L. C., Roze, E., Forlani, S., Gao, G., Frost, S., Frost, N., Sweadner, K. J., George, A. L., Lutz, C. M., & Liu, D. R. (2025). In vivo prime editing rescues alternating hemiplegia of childhood in mice. Cell, 188(16), 4275-4294.e23. https://doi.org/10.1016/j.cell.2025.06.038
Vancouver
Sousa AA, Terrey M, Sakai HA, Simmons CQ, Arystarkhova E, Morsci NS, et al. In vivo prime editing rescues alternating hemiplegia of childhood in mice. Cell. 2025;188(16):4275-4294.e23. doi:10.1016/j.cell.2025.06.038
BibTeX
@article{Sousa2025,
author = {Sousa, Alexander A and Terrey, Markus and Sakai, Holt A and Simmons, Christine Q and Arystarkhova, Elena and Morsci, Natalia S and Anderson, Laura C and Xie, Jun and Suri-Payer, Fabian and Laux, Linda C and Roze, Emmanuel and Forlani, Sylvie and Gao, Guangping and Frost, Simon and Frost, Nina and Sweadner, Kathleen J and George, Alfred L and Lutz, Cathleen M and Liu, David R},
title = {In vivo prime editing rescues alternating hemiplegia of childhood in mice},
journal = {Cell},
year = {2025},
volume = {188},
number = {16},
pages = {4275--4294.e23},
doi = {10.1016/j.cell.2025.06.038}
}
EUVIMED